Pharming’s Public Offer to Abliva

Vinge advised Abliva on the deal. Pharming Technologies B.V., a wholly owned subsidiary of Pharming Group N.V., has announced a public offer to the shareholders of...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Cantargia’s Rights Offering

Vinge advised Cantargia on the deal. Cantargia AB (publ) secured a rights offering of approximately SEK 170 million. Cantargia develops antibody based therapies against the target...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Trianon’s Shares Offering

Vinge advised Fastighets Aktiebolaget Trianon on the deal. Fastighets Aktiebolaget Trianon (publ) completed a directed share issue of SEK 184 million and a tender offer for...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Trianon’s Tender Offering

Vinge advised Fastighets Aktiebolaget Trianon on the deal. Fastighets Aktiebolaget Trianon (publ) completed a partial tender offer for outstanding subordinated perpetual floating rate callable sustainable capital...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Cantargia’s Shares Offering

Vinge advised Cantargia AB on the deal. Cantargia AB (publ) completed a directed share issue of approximately SEK 59 million (approx. $5.4 million) to a number of...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Procuritas’ €407 Million Fundraising

Vinge has advised Procuritas on the deal. The fund has received total commitments of EUR 407 million. PCI VII will continue Procuritas’ successful investment strategy of...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here